ClinicalTrials.gg
CompletedNCT06717269Updated Jul 28, 2026

A Single and Multiple Ascending Doses, Relative Bioavailability, Food Effect, and Drug-Drug Interaction Study of NX-5948 in Healthy Volunteers

A Phase 1 interventional study of NX-5948 and Esomeprazole in Healthy Volunteer, sponsored by Nurix Therapeutics, Inc.. Completed at 2 sites in United States. Open to participants aged 19 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-28.

Sponsored by Nurix Therapeutics, Inc. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
223
Allocation
Non-randomized
Ages
19 Years to 55 Years
Sex
All
01

Study summary

This is a multiple part, multiple cohort study evaluating single and multiple ascending doses, relative bioavailability, food effect, and drug-drug interaction of NX-5948 in healthy volunteers.

02

Conditions studied

  • Healthy Volunteer
03

In context

Lead sponsor

Nurix Therapeutics, Inc. is the lead sponsor of 10 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

  • Healthy, adult, male or female 19-55 years of age
  • Continuous non-smoker who has not used nicotine and tobacco-containing products for at least 3 months prior to the first dosing
  • (BMI) ≥ 18.0 and ≤ 32.0 kg/m2
  • Medically healthy with no medical history, physical examination, clinical laboratory profiles, or vital signs at the screening visit, as deemed by the Principal Investigator (PI) or designee
  • Understands the study procedures in the form (ICF) and be willing and able to comply with the protocol.

Key Exclusion Criteria:

  • Mentally or legally incapacitated or has significant emotional problems at the time of the screening visit or expected during the conduct of the study
  • Clinically significant history or presence of respiratory, gastrointestinal, renal, hepatic, hematological, lymphatic, neoplastic myeloproliferative, neurological, cardiovascular, psychiatric, musculoskeletal, genitourinary, immunological, dermatological, endocrine or connective tissue diseases or disorders
  • History of any gastrointestinal surgery or cholecystectomy that could impact the PK of NX-5948
  • History or presence of alcohol or drug abuse within the past 2 years
  • History or presence of , angioedema, or idiosyncratic reaction to the study drug(s) or related compounds
  • History or presence of:

    • Significant multiple and/or severe allergies, including anaphylactic reaction.
    • Personal or family history of prolonged syndrome or family history of sudden cardiac death.
    • Evidence of atrial fibrillation, atrial flutter, complete bundle branch block, Wolff Parkinson-White Syndrome, or cardiac pacemaker.
    • Adrenal insufficiency.
    • Skin infection.
  • Female volunteers of
  • Female volunteer with a positive pregnancy test
  • Positive results for (HIV), surface antigen (HBsAg), or virus (HCV) at the screening visit
  • Donation of blood or significant blood loss within 56 days prior to the first dosing
  • Plasma donation within 7 days prior to the first dosing
  • History or presence of clinically significant medical or psychiatric condition or disease in the opinion of the PI or designee.
  • Previous exposure to NX-5948.
  • Participation in another clinical study within 30 days or within 5 half-lives (if known), prior to the first dosing, whichever is longer. The 30-day window will be derived from the date of the last blood collection or dosing, whichever is later, in the previous study to Day 1 of Period 1 of the current study.

Note: Other Inclusion/Exclusion criteria may apply as defined in the protocol.

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
223 participants (actual)

Study arms

  • Experimental
    NX-5948 tablet and capsule under fasting and fed conditions; with and without placebo

    Drug: NX-5948 · Drug: Placebo

  • Experimental
    NX-5948 tablet and capsule with and without esomeprazole under fasting and fed conditions

    Drug: NX-5948 · Drug: Esomeprazole

  • Experimental
    NX-5948 with and without famotidine under fasting and fed conditions

    Drug: Famotidine · Drug: NX-5948

  • Experimental
    Midazolam with and without NX-5948

    Drug: Midazolam · Drug: NX-5948

  • Experimental
    Digoxin with and without NX-5948

    Drug: Digoxin · Drug: NX-5948

  • Experimental
    Rosuvastatin with and without NX-5948

    Drug: Rosuvastatin · Drug: NX-5948

  • Experimental
    NX-5948 with and without quinidine

    Drug: Quinidine · Drug: NX-5948

Interventions

  • Administered orally in tablet or capsule form

    Also known as: Bexobrutideg

  • DrugEsomeprazole

    Administered orally in capsule form

  • DrugPlacebo

    Administered orally matching NX-5948 tablets

  • DrugFamotidine

    Administered orally in tablet form

  • DrugMidazolam

    Administered orally in syrup form

  • DrugDigoxin

    Administered orally in tablet form

  • DrugRosuvastatin

    Administered orally in tablet form

  • DrugQuinidine

    Administered orally in tablet form

  • Administered in capsule form

    Also known as: Bexobrutideg

06

What researchers measure

Primary outcomes

  1. Area under the concentration-time curve from time 0 to last observed non-zero concentration (AUC0-t): NX-5948

    NX-5948 administered as a tablet or capsule under fasting and fed conditions; with and without esomeprazole, famotidine, or quinidine

    Time frame: 9 weeks

  2. Area under the concentration-time curve from time 0 extrapolated to infinity (AUC0-inf): NX-5948

    NX-5948 administered as a tablet or capsule under fasting and fed conditions; with and without esomeprazole, famotidine, or quinidine

    Time frame: 9 weeks

  3. Maximum observed concentration (Cmax): NX-5948

    NX-5948 administered as a tablet or capsule under fasting and fed conditions; with and without esomeprazole, famotidine, or quinidine

    Time frame: 9 weeks

  4. AUC0-t: Midazolam, rosuvastatin, or digoxin

    Midazolam, rosuvastatin, or digoxin administered with and without NX-5948

    Time frame: 9 weeks

  5. AUC0-inf: Midazolam, rosuvastatin, or digoxin

    Midazolam, rosuvastatin, or digoxin administered with and without NX-5948

    Time frame: 9 weeks

  6. Cmax: Midazolam, rosuvastatin, or digoxin

    Midazolam, rosuvastatin, or digoxin administered with and without NX-5948

    Time frame: 9 weeks

  7. Placebo-corrected change from baseline QT interval (QTc) as measured by electrocardiogram

    Time frame: Baseline, 9 weeks

  8. Number of participants with treatment-emergent adverse events

    Time frame: Up to 10 weeks

07

Study locations

2 sites
  • Celerion
    Phoenix, Arizona 85283, United States
  • Celerion
    Lincoln, Nebraska 68502, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2024 to primary completion in May 2026, 17 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 1, 2024
First posted
Dec 4, 2024
StartActual
Nov 30, 2024
Primary completionActual
May 1, 2026
CompletionActual
May 1, 2026
Last update
Jul 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06717269
Lead sponsor
Nurix Therapeutics, Inc.
Responsible party
Sponsor
First posted
Dec 4, 2024
Start date
Nov 30, 2024
Primary completion
May 1, 2026
Completion
May 1, 2026
Last update
Jul 28, 2026

Study contacts

Study Director
study director · Nurix Therapeutics

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: NX-5948

Start the discussion